Interestingly, VISTA was found to be upregulated in tumor tissue following standard immunotherapy of metastatic melanoma patients (35) and prostate cancer patients (36), suggesting VISTA as a possible combination partner for standard therapies. The gene discussed is VSIR; the disease is prostate carcinoma.